P27 (Negative Regulatory Factor or Nef)-Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0451TDB
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

P27 (Negative Regulatory Factor or Nef)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, P27 (Negative Regulatory Factor or Nef)-Pipeline Review, H2 2016', provides in depth analysis on P27 (Negative Regulatory Factor or Nef) targeted pipeline therapeutics.

The report provides comprehensive information on the P27 (Negative Regulatory Factor or Nef) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for P27 (Negative Regulatory Factor or Nef)

The report reviews P27 (Negative Regulatory Factor or Nef) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics and enlists all their major and minor projects

The report assesses P27 (Negative Regulatory Factor or Nef) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P27 (Negative Regulatory Factor or Nef) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P27 (Negative Regulatory Factor or Nef)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P27 (Negative Regulatory Factor or Nef) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

P27 (Negative Regulatory Factor or Nef) Overview 6

Therapeutics Development 7

P27 (Negative Regulatory Factor or Nef)-Products under Development by Stage of Development 7

P27 (Negative Regulatory Factor or Nef)-Products under Development by Therapy Area 8

P27 (Negative Regulatory Factor or Nef)-Products under Development by Indication 9

P27 (Negative Regulatory Factor or Nef)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

P27 (Negative Regulatory Factor or Nef)-Products under Development by Companies 12

P27 (Negative Regulatory Factor or Nef)-Products under Development by Universities/Institutes 14

P27 (Negative Regulatory Factor or Nef)-Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

P27 (Negative Regulatory Factor or Nef)-Drug Profiles 22

HIV vaccine-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

HIV vaccine-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

HIV vaccine 1-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

HIV-1 vaccine 1-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

HIV-1 vaccine 5-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Monoclonal Antibody Conjugate to Inhibit Gag, Nef, Pol for HIV-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

MVATG-17401-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules to Inhibit Nef for HIV-1 Infections-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Tatbeclin-1-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

P27 (Negative Regulatory Factor or Nef)-Dormant Projects 31

P27 (Negative Regulatory Factor or Nef)-Featured News & Press Releases 33

Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests 33

Appendix 34

Methodology 34

Coverage 34

Secondary Research 34

Primary Research 34

Expert Panel Validation 34

Contact Us 34

Disclaimer 35

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Dormant Projects, H2 2016 31

Dormant Projects (Contd..1), H2 2016 32

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

P27 (Negative Regulatory Factor or Nef) Therapeutic Products under Development, Key Players in P27 (Negative Regulatory Factor or Nef) Therapeutics, P27 (Negative Regulatory Factor or Nef) Pipeline Overview, P27 (Negative Regulatory Factor or Nef) Pipeline, P27 (Negative Regulatory Factor or Nef) Pipeline Assessment

select a license
Single User License
USD 3500 INR 249830
Site License
USD 7000 INR 499660
Corporate User License
USD 10500 INR 749490

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com